SCHEMBL455942

SCHEMBL455942

Cc1ccc(-c2cc(C(=O)O)cn3cnnc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.41
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
IP6K1 Q92551 1/20 0.39
IP6K3 Q96PC2 1/20 0.39
IP6K2 Q9UHH9 1/20 0.39
KDM4C Q9H3R0 3/20 0.38
KDM2B Q8NHM5 1/20 0.38
PDCD1 Q15116 3/20 0.37
CD274 Q9NZQ7 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12143897 0.87 ALDH1A1 (0.44) MAP4K4ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL452133 0.83 CA12 (0.34) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL454081 0.78 SPTLC1 (0.53) MAP4K4ALDH1A1KDM4EHPGDGAA
SCHEMBL455326 0.74 NR1H2 (0.41) MAP4K4ALDH1A1KDM4EHPGDGAA
SCHEMBL31132479 0.73 DDO (0.35) PDCD1CD274
SCHEMBL12754632 0.72 TTR (0.40) ALDH1A1POLBKDM4CKDM2B
SCHEMBL31133271 0.72 MAOB (0.40) MAPTSRD5A2ADH5
SCHEMBL28078965 0.68 RXRA (0.46) MAP4K4ALDH1A1KDM4EHPGDGAA
SCHEMBL19627078 0.67 ALDH1A1 (0.71) MAP4K4ALDH1A1KDM4EHPGDGAA
SCHEMBL2744390 0.66 GRIK1 (0.59) MAP4K4ALDH1A1KDM4EHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238647-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2016-01-19 US disclosed
EP-2410857-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2014-01-29 EP disclosed
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain MERCK SHARP & DOHME LLC 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064181-A1 P2X3 Receptor Antagonists for Treatment of Pain P2RX3, P2RX1, P2RX2 MAP4K4 2589/4885ALDH1A1 2538/4885KDM4E 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.